Venture Medical secures rights to ProgenaMatrix, revyve
By HME News Staff
Updated 9:34 AM CDT, Mon June 16, 2025
MISSOULA, Mont. – Venture Medical has acquired certain assets of ProgenaCare Global, a biotech company known for its innovative, keratin-based wound healing technologies, including ProgenaMatrix and intellectual property underlying an expected future product line. By integrating ProgenaCare's proprietary keratin platform, Venture Medical enhances its advanced therapy portfolio with regenerative technologies that accelerate healing and improve outcomes for patients with chronic and hard-to-heal wounds, the company says. “Between their comprehensive product formulary and proprietary Venture OneView platform, they are positioned to become a nationwide leader in the wound care space," said Bert Jones, chairman of the board of ProgenaCare Global. "We are excited to see our mission continue with a company that shares our values and has the infrastructure to scale our impact." Howard Walthall, former CEO of ProgenaCare, has joined Venture Medical as senior vice president of product development. The acquisition includes full rights to ProgenaMatrix, the first and only keratin matrix cleared by the U.S. Food and Drug Administration for wound management, and contractual rights to distribute revyve, an advanced antimicrobial hydrogel. Both products are now available through Venture Medical's distribution network.
Comments